The Centers for Medicare and Medicaid Services said it will cover the cost of the drug Aduhelm, but as part of further clinical testing.
Aduhelm on the condition that patients are in clinical trials and have early-stage symptoms.
A final decision is expected in April following an additional 30-day comment period in which members of the public can weigh in on the proposed coverage policy. Of the two studies, only one showed patients taking Aduhelm had a slowing in cognitive decline compared with patients receiving placebos. The conflicting results led to ongoing debate over whether the drug really works. As part of the FDA approval, Biogen and its partnerAduhelm has faced widespread criticism since its approval in June, in part because concerns that its priceif millions of patients start taking it.
Still, the policy could mean that it won’t be easy for many patients to receive treatment if they live in an area where there isn’t an eligible clinical trial, he added.— Ronald C. Petersen of the Mayo Clinic Alzheimer’s Disease Research Center
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Lire la suite »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Lire la suite »
U.S. Medicare plans to cover Biogen Alzheimer's drug only for trial patientsThe U.S. government Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's Aduhelm but will require patients to be enrolled in a clinical trial, potentially limiting access.
Lire la suite »
Medicare proposes only covering Alzheimer's drug Aduhelm for clinical trial patientsBiogen drug, the first in decades approved to treat the disease, has sparked concerns about its high cost and efficacy.
Lire la suite »
Medicare plans to pay for controversial Alzheimer’s drug, if patients enroll in trialsMedicare plans to provide insurance coverage for Aduhelm, a controversial Alzheimer’s treatment from drugmaker Biogen.
Lire la suite »
Medicare told to reassess premium hike after price slashed on Biogen Alzheimer's drugDepartment of Health and Human Services Secretary Xavier Becerra has asked Medicare to reassess its 2022 premium increase after Biogen slashed the cost of its expensive new Alzheimer's drug, which was part of the reason for the boost.
Lire la suite »